Compare AbbVie Inc (ABBV) vs Union Pacific Corporation (UNP) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs Union Pacific Corporation — how do they compare? AbbVie Inc trades at $253.77 (market cap $449.91B), while Union Pacific Corporation trades at $281.67 (market cap $168.09B). The key difference: AbbVie Inc is far larger — about 2.7× Union Pacific Corporation's market cap, and AbbVie Inc pays the higher dividend (2.72%). Which is the better fit depends on your goals.
| ABBV | UNP | |
|---|---|---|
Market Cap | $449.91B | $168.09B |
Sector | Health | Industrials |
52-Week High | $261.07 | $283.12 |
52-Week Low | $184.85 | $214.91 |
Enterprise Value | $513.38B | $198.56B |
Dividend Yield | 2.72% | 1.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $253.61, down 0.45% on the day, with strong technical momentum showing bullish moving averages and key support at $253. The company reported Q1 2026 EPS of $2.65, beating expectations, while revenue growth is supported by Skyrizi and Rinvoq offsetting Humira declines. Analysts maintain a bullish consensus with 68% buy ratings and a $266.33 price target, representing 5% upside potential.
The outlook remains positive with robust immunology portfolio performance and dividend growth, though risks include patent cliffs in the 2030s and competitive pressures. Current valuation metrics appear elevated with P/E at 124.83, requiring sustained earnings growth to justify premium multiples. The stock offers income appeal with consistent dividend payments while navigating portfolio transition.
Union Pacific (UNP) trades at $283.12, up 0.31% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported strong Q1 2026 earnings, beating estimates with EPS of $2.93, and maintains robust profitability with a 29.2% net margin. Recent news highlights the ongoing merger process with Norfolk Southern and a class action lawsuit regarding environmental concerns.
Outlook remains positive with a consensus price target of $290.55, indicating potential upside. Key risks include regulatory scrutiny of the merger and legal challenges. The stock's valuation multiples are elevated, but solid cash flow and dividend growth support investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the U.S., UP generated roughly $22 billion of revenue in 2021 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, and automotive goods. UP owns about one fourth of Mexican railroad Ferromex and derives about 10% of its revenue hauling freight to and from Mexico.
Read more on UNP →
